Health News

The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage.

Read more

Filed under: Pharmacy News
Tags: brain, cancer, Drug, Pharmacy, skin cancer, Tumor

Related posts

• Single dose of Pain Therapeutics’ PTI-188 decreased melanoma tumors: Study (0)
  Pain Therapeutics, Inc. today announced encouraging clinical data with PTI-188, an early-stage drug for metastatic melanoma. Metastatic melanoma is a lethal form of skin cancer in which patients typically have a median survival time of 9 months. Read more [tags] Pharmacy News [/tags]
  
  
• Researcher tackles deadly brain tumors (0)
  Natalie Ciaccio, a fourth-year graduate student researcher in the Department of Pharmaceutical Chemistry at the University of Kansas, is investigating what might be an ideal target for anti-cancer drug therapy, and she is focusing her work on brain tumors specifically. Read more [tags] Pharmacy News [/tags]
  
  
• Genentech’s Hedgehog Signal Inhibitor Helped Patients With Advanced Skin And Brain Cancers (0)
  A new type of experimental anti-cancer drug developed by Genentech, which inhibits the hedgehog signalling pathway, was effective in treating patients with advanced skin cancer. It was also very effective at first in treating a patient with an advanced type of brain cancer, and initial results were [...]
  
  
• Cotton-Seed Based Drug Shows Promise In Treating Severe Brain Cancer (0)
  An experimental drug derived from cottonseed shows promise in treating the recurrence of glioblastoma multiforme, widely considered the most lethal brain cancer, said researchers at the University of Alabama at Birmingham (UAB). The new results are from a Phase II clinical trial of AT-101, a pill manufactured from a potent compound in [...]
  
  
• Celldex commences CDX-011 Phase 2b trial in advanced breast cancer patients expressing GPNMB (0)
  Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, [...]